Remove tag biosimilars
article thumbnail

Cost of disease-modifying therapies for multiple sclerosis continues to rise in US

Pharmaceutical Technology

DMTs for MS have a high price tag, particularly in the US. A similar trend of price increases was also seen for MS generics and biosimilars. However, they cannot provide a cure and have a very limited impact on halting disease progression.

article thumbnail

Pioneering the Path Pre- and Post-Launch Strategies

PM360

In the swiftly changing realm of advanced therapies like biosimilars, rare disease molecules, and cell and gene therapies, a strong scientific interpretation and orientation is essential. Teams are stepping up to this challenge, actively shaping the trajectory of new interventions right from their inception.

Medical 52